Lipocine $LPCN announced that it met with the FDA and discussed the Complete Response Letter (CRL) it got in June in connection to its New Drug Application (NDA) seeking approval of lead product candidate LPCN 1021 (branded as Tlando) for testosterone replacement therapy in adult male.